The following are some of today’s top gainers in the pharma/biotech sector.
1. Krystal Biotech Inc. (KRYS)
Gained 27.55% to close Monday’s (Oct.15) trading at $20.00.
News: The Company announced positive interim results from its ongoing placebo-controlled phase I/II clinical trial of KB103 to treat dystrophic epidermolysis bullosa, or DEB.
DEB is an incurable, often fatal skin blistering condition caused by a lack of collagen protein in the skin. It is caused by mutations in the gene coding for type VII collagen, or COL7.
In the study, two adult DEB patients aged 35 and 28 years old have completed treatment with topical, gene therapy candidate KB103 to date. Results on the 2 patients met all primary efficacy and safety endpoints in topically administered KB103 wounds.
The phase I/II study is scheduled to be completed in the first half of 2019, and a pivotal phase III study is anticipated to commence in 2H 2019.
To know more about KRYS, please visit our “In the Spotlight” column.
2. XTL Biopharmaceuticals Ltd. (XTLB)
Gained 23.33% to close Monday’s trading at $2.96.
XTL Biopharma is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases.
News: No news
3. Cronos Group Inc. (CRON)
Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across five continents.
Gained 19.07% to close Monday’s trading at $11.74.
News: The Company has entered into a sponsored research agreement with the Technion Research and Development Foundation of the Technion – Israel Institute of Technology to explore the use of cannabinoids and their role in regulating skin health and skin disorders.
The preclinical studies will be conducted by Technion over a three-year period and will focus on three skin conditions namely, acne, psoriasis and skin repair.
4. Anixa Biosciences Inc. (ANIX)
Anixia, formerly known as ITUS Corp., is a biotechnology company focused on using the body’s immune system to fight cancer.
Gained 14.26% to close Monday’s trading at $6.33.
News: The Company has filed an IVD pre-submission with the FDA for use of its Cchek artificial intelligence based cancer detection technology, as a prostate cancer test.
A face-to-face meeting with the FDA has been sought by the Company to discuss the agency’s feedback on the proposed preclinical and clinical performance testing plan required to support a pre-market application, and to determine the appropriate regulatory path for Cchek.
5. Canopy Growth Corp. (CGC)
Canopy Growth is a diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms.
Gained 14.24% to close Monday’s trading at $56.89.
News: The Company has entered into an agreement to acquire the assets of ebbu Inc., an Evergreen, Colorado-based hemp research leader. In exchange for the assets being acquired, Canopy Growth will pay C$25 million in cash and issue 6,221,210 Company common shares to ebbu.
The Company is slated to release financial results for the second quarter fiscal 2019 ended September 30, 2018 on November 14, 2018.
For comments and feedback contact: firstname.lastname@example.org